Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.
Chitose T, Hokimoto S, Oshima S, Nakao K, Fujimoto K, Miyao Y, Shimomura H, Tsunoda R, Maruyama H, Hirose T, Yamamoto K, Mizobe M, Kaikita K, Nakamura S, Ogawa H; Kumamoto Intervention Conference Study (KICS) Investigators. Chitose T, et al. Circ J. 2012;76(1):71-8. doi: 10.1253/circj.cj-11-0699. Epub 2011 Dec 1. Circ J. 2012. PMID: 22130313 Free article.
Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.
Yamamoto K, Hokimoto S, Chitose T, Morita K, Ono T, Kaikita K, Tsujita K, Abe T, Deguchi M, Miyagawa H, Saruwatari J, Sumida H, Sugiyama S, Nakagawa K, Ogawa H. Yamamoto K, et al. Among authors: chitose t. J Cardiol. 2011 Mar;57(2):194-201. doi: 10.1016/j.jjcc.2010.10.007. Epub 2010 Dec 17. J Cardiol. 2011. PMID: 21168310 Free article.
Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
Hokimoto S, Chitose T, Mizobe M, Akasaka T, Arima Y, Kaikita K, Iwashita S, Morita K, Miyazaki H, Oniki K, Matsui K, Nakagawa K, Ogawa H. Hokimoto S, et al. Among authors: chitose t. Eur J Clin Pharmacol. 2014 Jun;70(6):667-73. doi: 10.1007/s00228-014-1672-3. Epub 2014 Apr 26. Eur J Clin Pharmacol. 2014. PMID: 24763934 Clinical Trial.
Intravascular ultrasound morphology of culprit lesions and clinical demographics in patients with acute coronary syndrome in relation to low-density lipoprotein cholesterol levels at onset.
Takaoka N, Tsujita K, Kaikita K, Hokimoto S, Yamanaga K, Komura N, Chitose T, Ono T, Mizobe M, Horio E, Sato K, Nakayama N, Saito M, Iwashita S, Kojima S, Tayama S, Sugiyama S, Nakamura S, Ogawa H. Takaoka N, et al. Among authors: chitose t. Heart Vessels. 2014 Sep;29(5):584-95. doi: 10.1007/s00380-013-0401-7. Epub 2013 Aug 28. Heart Vessels. 2014. PMID: 23982317
Validation of the obesity paradox by body mass index and waist circumference in patients undergoing percutaneous coronary intervention.
Shirahama Y, Tabata N, Sakamoto K, Sato R, Yamanaga K, Fujisue K, Sueta D, Araki S, Takashio S, Arima Y, Hokimoto S, Sato K, Sakamoto T, Nakao K, Shimomura H, Matsumura T, Tayama S, Fujimoto K, Oshima S, Nakamura S, Tsunoda R, Hirose T, Kikuta K, Sakaino N, Yamamoto N, Kajiwara I, Suzuki S, Yamamoto E, Kaikita K, Matsushita K, Tsujita K; Kumamoto Intervention Conference Study (KICS) Investigators. Shirahama Y, et al. Int J Obes (Lond). 2022 Oct;46(10):1840-1848. doi: 10.1038/s41366-022-01163-7. Epub 2022 Jul 28. Int J Obes (Lond). 2022. PMID: 35902692
Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction.
Nakamura Y, Yamada Y, Shimomura H, Nagayoshi Y, Tsujita K, Yamashita T, Fukuda M, Ohba K, Nako H, Ogura Y, Chitose T, Yamaguchi M, Nagata T, Soejima H, Kaikita K, Sugiyama S, Ogawa H. Nakamura Y, et al. Among authors: chitose t. J Cardiol. 2009 Dec;54(3):416-24. doi: 10.1016/j.jjcc.2009.07.001. Epub 2009 Aug 20. J Cardiol. 2009. PMID: 19944317 Free article. Clinical Trial.
Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation.
Shirahama R, Ono T, Nagamatsu S, Sueta D, Takashio S, Chitose T, Fujisue K, Sakamoto K, Yamamoto E, Izumiya Y, Kaikita K, Hokimoto S, Hori M, Harada-Shiba M, Kajiwara I, Ogawa H, Tsujita K. Shirahama R, et al. Among authors: chitose t. Intern Med. 2018;57(24):3551-3557. doi: 10.2169/internalmedicine.1060-18. Epub 2018 Dec 15. Intern Med. 2018. PMID: 30555118 Free PMC article.
16 results